AMAG Pharmaceuticals
1100 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-498–3300
Fax: 617-499-3361
Website: http://www.amagpharma.com/
Email: contactus@amagpharma.com
About AMAG Pharmaceuticals
Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
374 articles about AMAG Pharmaceuticals
-
AMAG Pharmaceuticals, Inc. Provides Additional Clinical Information on Ferumoxytol as an Intravenous Iron Replacement Therapeutic in Chronic Kidney Disease Patients
1/31/2008
-
AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
1/23/2008
-
AMAG Pharmaceuticals, Inc. Reports on Progress Toward Commercialization and Discusses Key Activities for 2008 at 26th Annual JPMorgan Healthcare Conference
1/8/2008
-
AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients
12/19/2007
-
AMAG Pharmaceuticals, Inc. Withdraws Marketing Authorization Application for Sinerem(TM) in Europe
12/13/2007
-
AMAG Pharmaceuticals, Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
12/10/2007
-
AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic in the Elderly at the American Society of Hematology Annual Meeting
12/10/2007
-
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended September 30, 2007
10/26/2007
-
AMAG Pharmaceuticals, Inc. to Host Quarterly Earnings Conference Call to Discuss September 30, 2007 Results
10/12/2007
-
AMAG Pharmaceuticals, Inc. Announces Eight Abstracts on Ferumoxytol to Be Presented at Upcoming American Society of Nephrology Meeting
10/10/2007
-
AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
9/5/2007
-
AMAG Pharmaceuticals, Inc. Announces Appointment of Lee F. Allen, M.D., Ph.D. as Chief Medical Officer and Senior Vice President of Clinical Development
8/7/2007
-
AMAG Pharmaceuticals, Inc. to Present at CANACCORD Adams 27th Annual Global Growth Conference
7/31/2007
-
Advanced Magnetics, Inc. Announces Name Change to AMAG Pharmaceuticals, Inc.
7/25/2007